Aortic stenosis with cardiac amyloidosis: much more than just another TAVI patient at IHF Course 2026

A key case-based discussion at iHF Course 2026 – introduced by Giuseppe Rosano

Managing aortic stenosis (AS) with coexisting cardiac amyloidosis is one of the most challenging clinical scenarios in structural heart disease. Differentiating "classic AS" from AS with disproportionate left ventricular hypertrophy (LVH) driven by amyloid infiltration fundamentally changes the diagnostic work-up, the expected outcome after TAVI and the patient’s long-term management.

In this short video, Giuseppe Rosano explains why this session is essential for any physician evaluating TAVI candidates with suspected or confirmed cardiac amyloidosis, and how understanding this AS-amyloidosis overlap can transform decision-making in daily practice.

Aortic stenosis with cardiac amyloidosis: much more than just another TAVI patient

Friday 20 March 2026 • 14:55–15:55

What you will learn

This case-based session sharpens your approach to aortic stenosis with suspected cardiac amyloidosis, focusing on the diagnostic and therapeutic decisions physicians search for most frequently. You’ll learn:

  • How to identify disproportionate LVH in AS and why a complete diagnostic work-up is essential to detect cardiac amyloidosis early
  • How underlying amyloidosis influences TAVI outcomes, procedural strategy and post-TAVI prognosis
  • Which post-TAVI pharmacologic therapies are recommended in patients with ATTR or AL amyloidosis, and how to structure optimal follow-up

All concepts are illustrated through one evolving real-world case, giving you a clear framework for evaluating AS with red flags for amyloidosis and deciding when TAVI is appropriate.

Why you should attend

If you manage patients with aortic stenosis, unexplained LVH, or suspected cardiac amyloidosis, this session will help you:

  • Distinguish isolated AS from AS + amyloidosis
  • Understand the clinical implications of TAVI in ATTR-CA or AL amyloidosis
  • Build an integrated pathway combining imaging, hemodynamics, TAVI planning and pharmacologic therapy

 

You will leave with a sharper, evidence-based approach to selecting the right TAVI candidates and improving outcomes in this high-risk population.

 

Interested?  Join us at iHF Course 2026: 

Register now!